Follow Intuitive Surgical to never miss an important update.
HSBC lowered its rating on the company to hold, a neutral stance that suggests the stock may not have much room to rise in the near term. The firm set a price target of $391, which is significantly lower than the average analyst target of $491.
This move reflects a more cautious view on the company's valuation after it warned about potential changes in insurance plans that could affect demand for its surgical robots. While the business remains a leader in robotic surgery, analysts are weighing whether the current stock price already accounts for its future growth.
Source: HSBC
The company is collaborating with Deion "Coach Prime" Sanders to increase public awareness of robotic-assisted surgery. The goal is to help patients better understand the different options available to them when they need medical procedures. While this is a high-profile marketing move, it does not change the core business. It is a routine effort to keep the company's technology top-of-mind for patients who might otherwise choose traditional surgery.
Source: GlobeNewsWire
At a recent industry conference, the company detailed its plans to integrate artificial intelligence into its surgical platforms. The goal is to use data from millions of procedures to help surgeons perform better and help hospitals manage their operating rooms more efficiently. This is a key part of the company's long-term strategy to stay ahead of new competitors. By using AI to provide feedback that other companies cannot yet match, it aims to make its robots even more essential to the hospitals that use them.
Source: GlobeNewsWire
The stock fell about 11 percent following the company's quarterly report. Although profits and revenue were higher than analysts expected, the company did not raise its growth forecast for the rest of the year and noted that procedure growth in the U.S. was slower than some had hoped.
For a company valued on high growth, even a small slowdown or a cautious outlook can cause a sharp drop in the stock price. The concern is that weight-loss drugs or changes in insurance coverage could be starting to affect the number of surgeries being performed.
Source: Proactive Investors
The company reported second-quarter revenue of about 2.89 billion dollars, up 19 percent from last year. It earned $2.80 per share, which was better than the $2.48 analysts expected. The number of surgeries performed with its robots grew 16 percent globally, led by a 36 percent jump in its Ion system used for lung biopsies.
A key part of the company's future is the rollout of its newest flagship robot, the da Vinci 5. It placed 246 of these new systems during the quarter, up from 180 a year ago. This suggests that hospitals are willing to spend on the latest technology even as the company keeps its overall growth forecast for the year steady. The total number of robots in hospitals reached 11,710, a 12 percent increase. This growing base is vital because it locks in recurring revenue from the specialized tools and services each machine requires for every surgery.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Analysts recently showed a flurry of activity in mid-July as they adjusted their outlooks following the company's latest performance updates. Most analysts remain positive, with 40 of 57 rating the stock a buy and an average target price suggesting 25% upside.
The company has a perfect record of beating analyst targets over the last two years. Management consistently sets a bar they can clear, even while growing revenue at a fast clip.
| Expectation | |
|---|---|
| EPS | $2.61 |
| Revenue | $2.91B |
Follow Intuitive Surgical to get the latest and most important updates.
Follow ISRG